Effects of rosuvastatin in different doses on myocardial indexes, serum lipid level and adverse cardiovascular events in patients with coronary heart disease after percutaneous coronary intervention

Abstract

Objective To observe the effects of rosuvastatin in different doses on myocardial indexes, serum lipid level and adverse cardiovascular events in patients with coronary heart disease (CHD) after percutaneous coronary intervention (PCI). Methods Eighty-six patients with CHD treated by PCI in Nanyang First People’s Hospital from March 2018 to March 2019 were selected. According to random number table method, they were divided into control group and observation group, with 43 cases in each group. The control group was treated with rosuvastatin calcium, 5 mg/time, 1 time/day; while the observation group was treated with rosuvastatin calcium, 10 mg/time, 1 time/day. The serum lipid levels, such as total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C), inflammatory factors, such as interleukin-6 (IL-6), C-reactive protein (CRP), myocardial indicators, such as troponin-I (cTn-I), creatine kinase (CK), creatine kinase isoenzyme (CK-MB), incidence of adverse cardiovascular events and drug adverse reactions were compared between the two groups. Results After treatment, the levels of TC, TG, LDL-C, IL-6, CRP, cTn-I, CK and CK-MB in the two groups were lower than those before treatment, and the above indexes in the observation group were lower than those in the control group (P 0.05). Conclusions The advantages of high-dose rosuvastatin in treatment of CHD patients after PCI is more significant than low-dose rosuvastatin in adjusting their serum lipid level, reducing inflammatory response, protecting cardiomyocytes and reducing adverse cardiovascular events. Key words: Coronary disease; Intervention surgery; Rosuvastatin; Myocardial index; Serum lipid level